Immune biomarkers and response to checkpoint inhibition of BRAF V600 and BRAF non-V600 altered lung cancers.
Yonina R Murciano-GoroffTerry PakSebastian MondacaJessica R FlynnJoseph MontecalvoNatasha RekhtmanDarragh HalpennyAndrew J PlodkowskiStephanie L WuMark G KrisPaul K PaikGregory J RielyHelena A YuCharles M RudinMatthew D HellmannJosiah D LandLarry W BuieGlenn HellerPiro LitoRona YaegerAlexander E DrilonDazhi LiuBob T LiMichael D OffinPublished in: British journal of cancer (2021)
A subset of patients with BRAF-altered lung cancers achieved durable disease control on ICI. However, collectively no significant clinical benefit was seen.